IRIS
MARCHETTI, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.862
EU - Europa 4.889
AS - Asia 4.849
SA - Sud America 632
Continente sconosciuto - Info sul continente non disponibili 350
AF - Africa 85
OC - Oceania 13
Totale 19.680
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.529
SG - Singapore 2.079
CN - Cina 1.319
IT - Italia 782
UA - Ucraina 701
IE - Irlanda 652
RU - Federazione Russa 545
GB - Regno Unito 524
BR - Brasile 510
SE - Svezia 481
DE - Germania 413
TR - Turchia 409
VN - Vietnam 370
FR - Francia 345
FI - Finlandia 206
IN - India 199
CA - Canada 160
HK - Hong Kong 115
BD - Bangladesh 64
MX - Messico 54
PL - Polonia 46
AR - Argentina 43
KR - Corea 40
IQ - Iraq 37
CZ - Repubblica Ceca 32
JP - Giappone 31
NL - Olanda 26
ID - Indonesia 25
BE - Belgio 24
ES - Italia 24
IL - Israele 23
EC - Ecuador 22
PK - Pakistan 22
CR - Costa Rica 21
ZA - Sudafrica 20
TW - Taiwan 19
AT - Austria 18
CO - Colombia 15
SA - Arabia Saudita 15
JM - Giamaica 14
MY - Malesia 14
NI - Nicaragua 14
SC - Seychelles 14
VE - Venezuela 14
GT - Guatemala 13
AE - Emirati Arabi Uniti 12
LT - Lituania 12
MA - Marocco 12
EE - Estonia 11
IR - Iran 11
PR - Porto Rico 11
SV - El Salvador 11
CL - Cile 10
EU - Europa 10
KE - Kenya 10
TT - Trinidad e Tobago 10
PY - Paraguay 9
AU - Australia 8
HN - Honduras 8
CH - Svizzera 7
GP - Guadalupe 7
CW - ???statistics.table.value.countryCode.CW??? 6
LB - Libano 6
BA - Bosnia-Erzegovina 5
ET - Etiopia 5
GR - Grecia 5
MK - Macedonia 5
NO - Norvegia 5
NZ - Nuova Zelanda 5
PH - Filippine 5
TN - Tunisia 5
DZ - Algeria 4
EG - Egitto 4
GE - Georgia 4
JO - Giordania 4
UY - Uruguay 4
AZ - Azerbaigian 3
BG - Bulgaria 3
NG - Nigeria 3
NP - Nepal 3
PE - Perù 3
RO - Romania 3
SN - Senegal 3
TH - Thailandia 3
UG - Uganda 3
UZ - Uzbekistan 3
AM - Armenia 2
BO - Bolivia 2
BS - Bahamas 2
DK - Danimarca 2
GD - Grenada 2
MN - Mongolia 2
PA - Panama 2
RS - Serbia 2
AL - Albania 1
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
BM - Bermuda 1
BN - Brunei Darussalam 1
Totale 19.326
Salva come PNG Salva come JPEG
Città #
Singapore 1.558
San Jose 944
Jacksonville 840
Chandler 817
Dublin 641
Ashburn 499
Council Bluffs 375
Beijing 339
Princeton 322
Dallas 316
Southend 286
Izmir 238
Nanjing 237
Santa Clara 209
Los Angeles 194
Munich 153
Wilmington 134
Cambridge 131
New York 129
Dearborn 117
Ho Chi Minh City 116
Tongling 114
Altamura 108
Hong Kong 105
Buffalo 104
The Dalles 104
Boardman 90
Ann Arbor 88
North Bergen 84
Hanoi 73
Nanchang 71
Chieti 68
Helsinki 63
Pescara 63
Shenyang 55
Moscow 51
Rome 50
São Paulo 49
Milan 48
Phoenix 48
Redondo Beach 44
Atlanta 41
Chicago 41
Brooklyn 39
Denver 39
Hebei 39
Tianjin 39
Seoul 37
Warsaw 37
Kimball 36
Woodbridge 36
Montreal 34
Orem 32
Kunming 31
Hangzhou 28
Houston 27
Toronto 27
Columbus 26
Washington 26
Chennai 25
Grevenbroich 24
London 24
Tokyo 24
Norwalk 23
Rio de Janeiro 23
Augusta 22
Boston 22
Mexico City 22
Stockholm 22
Frankfurt am Main 20
Jiaxing 20
Brussels 19
San José 19
Collecorvino 18
Da Nang 18
Poplar 18
Baghdad 17
Hefei 17
Nuremberg 17
San Mateo 17
Belo Horizonte 16
Brno 16
Orange 16
Agrolândia 15
Johannesburg 15
Philadelphia 14
San Francisco 14
Taichung 14
Changsha 13
Guangzhou 13
Latina 13
Managua 13
Turku 13
Claxton 12
Haiphong 12
Miami 12
Seattle 12
Vienna 12
Fairfield 11
Hyderabad 11
Totale 11.388
Salva come PNG Salva come JPEG
Nome #
Developing a Decision-making Model Based on an Interdisciplinary Oncological Care Group for the Management of Colorectal Cancer 288
Assessing EGFR mutations. 273
ALK protein analysis by IHC staining after recent regulatory changes: A comparison of two widely used approaches, revision of the literature, and a new testing algorithm 239
A unique microRNA signature associated with plaque instability in humans. 224
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: Toward a real-time liquid biopsy for treatment 222
A multidisciplinary group for prostate cancer management: A single institution experience 205
ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: Results of the first italian external quality assurance scheme 203
Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays 199
Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. 196
A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. 181
Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors 175
Analysis of DNA Glycosylases MUTYH and OGG1 and Their Correlation with EGFR Signalling in Normal and Nodular Thyroid Tissues 173
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. 169
A unique microRNA signature associated with ischemic stroke in humans 169
ROS1 Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm 167
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. 166
Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. 162
Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. 161
AKT1(E17K) in human solid tumours 161
KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment. 160
HIGH-RISK HUMAN PAPILLOMA VIRUS INFECTION, TUMOR PATHOPHENOTYPES AND BRCA1/2 AND P53 STATUS IN JUVENILE BREAST CANCER PATIENTS. 159
Mutational profile of GNAQQ209 in human tumors. 159
POLE exonuclease domain mutations in endometrial carcinoma: a case report 156
Int6 expression can predict survival in early-stage non-small cell lung cancer patients. 156
Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series. 155
Down regulation of high in normal-1 (HIN-1) is a frequent event in stage I non-small cell lung cancer and correlates with poor clinical outcome. 155
ATP-binding cassette transporter A1 (ABCA1) overexpression in hypercholesterolemic plaques: a potential molecular explanation 154
Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle 152
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. 151
Evaluation of DNA Base Excision Repair and ErbB signaling in euthyroid goiters 151
Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project 149
Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma. 148
2nd ESMO consensus conference on lung cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up 148
2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer 145
Overexpression of ABCA1 in human plaques exposed to hypercholesterolemia: the role of microRNA modulation 144
Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. 143
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: A new algorithm for patient selection and personalized treatment 143
Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas. 142
Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer 142
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice 141
Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early Predictor of Clinical Response to Tyrosine Kinase Inhibitor 140
Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe 139
Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications. 138
Survivin gene expression in early-stage non-small cell lung cancer. 136
Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation 136
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. 136
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. 136
Absence of somatic mutations in the coding region of the waf1/cip1 gene in human breast, lung and ovarian carcinomas - a polymorphism at codon-31. 136
Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. 135
Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients 135
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 135
Association between cigarette smoking and FHIT gene alterations in lung cancer. 133
An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatments 133
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors. 132
Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations 132
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. 131
Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry — Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort 131
Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. 129
microRNAs Derived from Circulating Exosomes as Noninvasive Biomarkers for Screening and Diagnosing Lung Cancer. 129
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. 129
mRNA markers of breast cancer nodal metastases: comparison between mammaglobin and carcinoembryonic antigen in 248 patients. 128
Correspondence - In Reply - Limitations of Single-Strand Conformation Polymorphism Analysis As a High-Throughput Method for the Detection of EGFR Mutations in the Clinical Setting 127
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. 127
Telomerase activity as a prognostic indicator in Stage I Non- Small Cell Lung Cancer -Gruppo Italiano di Patologia Molecolare II Riunione Scientifica. Pisa 20-22 Giugno99 126
Ventana ALK (D5F3) in the Detection of Patients Affected by Anaplastic Lymphoma Kinase-positive Non–Small-cell Lung Cancer: Clinical and Budget Effect 126
Loss of beta4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation. 125
Hypertension is a determinant of ABCA1 expression in atherosclerotic plaques from hypercholesterolemic patients 125
2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer first-line/second and further lines in advanced disease 125
p53 alterations in non-small cell lung cancer correlate with metastatic involvement of hilar and mediastinal lymph nodes 124
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. 124
Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients 124
Lung tumours from non-smoking subjects: A p53-related genetic instability in a subset of cases. 123
MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. 123
Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up 122
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 122
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: Results from the ETOP Lungscape Project 122
mdm2 gene alterations and mdm2 protein expression in breast carcinomas 121
Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project 121
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies 119
Enriched SSCP: a highly sensitive method for the detection of unknown mutations. Application to the molecular diagnosis of lung cancer in sputum samples. 118
The chromosomal location of the mouse mammary tumor gene Int6 and related pseudogenes in the mouse genome. 118
The chromosome location of the human homolog of the mouse mammary tumor-associated gene INT6 and its status in human breast carcinomas. 117
Host genetic background effect on the frequency of mouse mammary tumor virus-induced rearrangements of the int-1 and int-2 loci in mouse mammary tumors. 117
Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. 117
Hypertension modulates miR-145 expression in human atherosclerotic plaques 117
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies 117
Genetic analysis of lung tumors of non-smoking subject: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus 115
The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. 115
Int-6, a highly conserved, widely expressed gene, is mutated by mouse mammary tumor virus in mammary preneoplasia. 112
Molecular profiling of the "plexinome" in melanoma and pancreatic cancer. 112
A percutaneous large-needle aspiration biopsy technique for histologic examination of the testis in infertile patients. 112
Nucleotide and deduced amino acid sequences of tumor gene INT6. 111
Bronchioloalveolar carcinoma: K-ras mutations are constant events in the mucinous subtype 108
Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. 108
BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients 108
BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report 107
Real-world data on NGS diagnostics: A survey from the Italian Society of Pathology (SIAPeC) NGS Network 107
Telomerase Activity as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer 106
K-ras mutations and cetuximab in colorectal cancer. 106
p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. 104
Totale 14.273
Salva come PNG Salva come JPEG
Categoria #
all - tutte 79.846
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 79.846
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022620 0 0 0 0 53 34 24 55 64 39 106 245
2022/20232.259 218 305 105 266 227 443 137 144 287 15 64 48
2023/20241.000 88 27 63 28 67 294 206 42 11 33 6 135
2024/20253.145 156 596 498 72 74 123 164 161 322 142 325 512
2025/20265.606 449 313 541 678 579 385 797 393 590 464 331 86
2026/20272.033 115 300 312 915 391 0 0 0 0 0 0 0
Totale 19.680